Earnings Call · Q3 FY2021·2021-11-04

Q3 21EPS -1.79%·Rev n/aQ2 21EPS +3.64%·Rev n/aQ1 21EPS +48.98%·Rev n/aQ4 20EPS +5.36%·Rev n/a⚠ consensus missing

Allogene Therapeutics, Inc. ALLO

Christine Cassiano — Investor Relations

David Chang — CEO

Rafael Amado — Chief Medical Officer

Eric Schmidt — CFO

+3.7%1d on move date+3.3% vs SPY3d−2.2%5d−1.0%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ALLO calls or request research access.

More ALLO calls Browse calls Request research access